Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), MUC1 inhibitors(Mucin-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | 04 Sep 2024 |